Medipaams India Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 16-11-2024
- Paid Up Capital ₹ 0.10 M
as on 16-11-2024
- Company Age 19 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 37.79%
(FY 2023)
- Profit -36.28%
(FY 2023)
- Ebitda 2039.50%
(FY 2023)
- Net Worth 12.08%
(FY 2023)
- Total Assets 44.34%
(FY 2023)
About Medipaams India
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Alpesh Popatlal and Abhi Munani serve as directors at the Company.
- CIN/LLPIN
U51397MH2005PTC154336
- Company No.
154336
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
29 Jun 2005
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Medipaams India Private Limited offer?
Medipaams India Private Limited offers a wide range of products and services, including Anti Infective Drugs & Medicines, Anti Allergic Drug, Antibiotic Injection, Cardiovascular Drugs & Medication, Diabetes Medicine, Injectable Products, Pharmaceutical Injectables, Arthritic Drugs, Aceclofenac Tablet, Antifungal Injection, Tablet & Syrup.
Who are the key members and board of directors at Medipaams India?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Alpesh Popatlal  | Director | 03-Aug-2005 | Current |
| Abhi Munani | Director | 18-May-2020 | Current |
Financial Performance of Medipaams India.
Medipaams India Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 37.79% increase. The company also saw a substantial fall in profitability, with a 36.28% decrease in profit. The company's net worth Soared by an impressive increase of 12.08%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Medipaams India?
In 2023, Medipaams India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Medipaams India?
Unlock and access historical data on people associated with Medipaams India, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Medipaams India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Medipaams India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
